| Drug General Information |
| Drug ID |
D0E1QI
|
| Former ID |
DIB020997
|
| Drug Name |
SU11274
|
| Synonyms |
Met kinase Inhibitor; SU-11274
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C28H30ClN5O4S
|
| InChI |
InChI=1S/C28H30ClN5O4S/c1-17-25(30-18(2)26(17)28(36)34-12-10-32(3)11-13-34)16-23-22-15-21(8-9-24(22)31-27(23)35)39(37,38)33(4)20-7-5-6-19(29)14-20/h5-9,14-16,30H,10-13H2,1-4H3,(H,31,35)/b23-16-
|
| InChIKey |
FPYJSJDOHRDAMT-KQWNVCNZSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14720363, 16865465, 22395876, 23984869, 24724625, 26759130, 29217660, 44692626, 57372718, 78782302, 85286099, 91722392, 99302720, 99436971, 103566217, 123051067, 124756984, 125163789, 126658547, 126726633, 131344572, 131408367, 131480750, 134964429, 136340172, 136367282, 136367776, 138602656, 139030286, 143496650, 152133983, 152237702, 152344163, 162011450, 162037422, 162202651, 163687719, 164043002, 172914483, 175607420, 177748770, 178101751, 179694511, 180438587, 186014494, 187071977, 204369725, 223377267, 223678026, 223705038
|
| Target and Pathway |
| Target(s) |
Hepatocyte growth factor receptor |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Adherens junction
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Malaria
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
Syndecan-1-mediated signaling events
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
FGF signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling Pathways in Glioblastoma
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 | Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr Drug Targets. 2001 Mar;2(1):41-55. |
|---|
| REF 2 | Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92. |
|---|
